SCHEMBL2015370

SCHEMBL2015370

Cc1cccc(-c2nnc(-c3cn4c5c(cccc35)CCC4)o2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
HPGD P15428 6/20 0.48
TSHR P16473 2/20 0.48
MAPT P10636 4/20 0.46
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 3/20 0.44
TP53 P04637 3/20 0.44
POLB P06746 1/20 0.44
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020405 0.89 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2021453 0.87 RAB9A (0.49) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2020106 0.87 RAB9A (0.48) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2023138 0.86 KDM4E (0.48) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2021179 0.84 RAB9A (0.51) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2018600 0.83 HTR2A (0.46) HPGDALDH1A1HSD17B10TP53HTR2A
SCHEMBL2021806 0.83 ALDH1A1 (0.44) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2015078 0.83 HTR2A (0.43) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL2017965 0.83 TP53 (0.42) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL2019352 0.82 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 NPC1 235/4885RAB9A 1649/4885SMN1; SMN2 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.